DOCSLIB.ORG

15 Jargin.Indd 86 2/5/2010 8:54:21 AM Concept of Serum Atherogenicity Questioned Jargin SV

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
15 Jargin.Indd 86 2/5/2010 8:54:21 AM Concept of Serum Atherogenicity Questioned Jargin SV Concept of Serum Atherogenicity Questioned Jargin SV • Letter to the editor • testing of Anti-atherogenic drugs and Food Components on Cell Cultures: Assessment of reliability therogenesis involves multiple cell types interacting anti-atherogenic agents (1), also cannot be reproduced in with each other and with extracellular matrix (1). a cell monoculture. In vivo, dependence between cellular ATherefore, results obtained on a single cell type cholesterol uptake and atherogenesis is inverse rather than should be considered with caution when extrapolated to the direct. For example, in familial hypercholesterolemia caused whole organism. A large series of studies, having become by abnormality of LDL-receptors (which are present also on internationally known in 1986 (2), has been continued the smooth muscle cells), inefficient clearance of LDL from until today by Orekhov and co-workers. Cultures of smooth the serum results in hypercholesterolemia and predisposition muscle cells from human aorta were used as a testing model to atherosclerosis (15-16). Accordingly, if a drug reduces for evaluation of serum atherogenicity and effectiveness of cholesterol uptake by cells in vitro, it should be expected to anti-atherogenic drugs and food components. The following cause blood cholesterol elevation in vivo (17). Therefore, the was reported: after 24 hours of cultivation with 40 % sera conclusions and recommendations regarding atherosclerosis from patients with coronary heart disease (CHD), the treatment and prevention, formulated on the basis of cell intracellular cholesterol level in the cultured smooth muscle culture experiments discussed above, can be disproven by cells increased twofold to fivefold; low density lipoproteins reductio ad absurdum: pharmacologic agents with an “anti- (LDL) from patients with CHD or diabetes mellitus caused atherogenic” effect in cell cultures should be expected to have a twofold to fourfold intracellular cholesterol elevation. a pro-atherogenic effect in vivo. On the contrary, the serum and LDL from healthy persons failed to induce lipid accumulation (3-4). Furthermore, after 24 hours, calcium antagonists (verapamil, nifedipine, Sergei V. Jargin darodipine, isradipine, diltiazem, etc.) reduced cholesterol Peoples’ Friendship University of Russia level in cultured cells, whereas beta-blockers (propranolol, Clementovski per 6-82; 115184 Moscow, Russia. alprenolol, metoprolol, atenolol, pindolol, and timolol) Telephone and Fax: +7 495 9516788 caused a 1.5- to twofold rise of cholesterol content in the Email: [email protected] cells, cultured from an atherosclerotic plaque (5). In a handbook of therapeutics (6) these data were summarized, references and clinical recommendations given on their basis. Among substances, demonstrating anti-atherogenic effectiveness in 1. Mundo-Sagardía JA, Figueroa Y, Altieri PI, Banchs HL, Escobales N, vitro, the following were listed: statins, trapidil, prostaglandin Crespo MJ. The atherosclerotic plaque. P R Health Sci J 2008;27:241-246. E2, dibutyryl cyclic AMP, calcium channel blockers, 2. Chazov EI, Tertov VV, Orekhov AN, Lyakishev AA, Perova NV, Kurdanov KA, Khashimov KA, Novikov ID, Smirnov VN. Atherogenicity of blood lipoxygenase and acetylcholinesterase inhibitors, carbacyclin; serum from patients with coronary heart disease. Lancet 1986;2:595-598. and among pro-atherogenic substances - beta-adrenergic 3. Orekhov AN, Tertov VV, Pokrovsky SN, Adamova IYu, Martsenyuk ON, blockers, phenothiazines, oral hypoglycemics etc. The same Lyakishev AA, Smirnov VN. Blood serum atherogenicity associated with data were published in peer-reviewed journals (7-11). For coronary atherosclerosis. Evidence for nonlipid factor providing athero- example, clinical recommendations were published in a genicity of low-density lipoproteins and an approach to its elimination. Circ Res 1988;62:421-429. pharmacological journal (12), including dosages of drugs, 4. Tertov VV, Orekhov AN, Sobenin IA, Gabbasov ZA, Popov EG, Yaro- calculated on the basis of cell culture experiments: “To slavov AA, Smirnov VN. Three types of naturally occurring modified decrease atherogenic potential of serum and to maintain it at a lipoproteins induce intracellular lipid accumulation due to lipoprotein low level, verapamil should be administered at a dose of 40mg aggregation. Circ Res 1992;71:218-228. 5. Orekhov AN, Baldenkov GN, Tertov VV, Ryong LH, Kozlov SG, Lya- 5 times daily with a 4- to 5-hour interval between doses” (12). kishev AA, Tkachuk VA, Ruda MYa, Smirnov VN. Cardiovascular drugs However, known action mechanisms of anti-atherogenic and atherosclerosis: effects of calcium antagonists, beta-blockers, and or lipid-lowering agents include regulation of cholesterol nitrates on atherosclerotic characteristics of human aortic cells. J Cardio- synthesis, lipid and lipoprotein metabolism in the liver, vasc Pharmacol 1988;12(Suppl 6):S66-S68. 6. Pivovarova EM. Treatment of Atherosclerosis (In Russian). In: Clinical An- intestinal absorption, and influence upon the endothelium- giology. (Pokrovsky AV, ed), Moscow; Meditsina, v. 2, 2004, p. 712-714. related factors (13-14). All these targets are absent in cell 7. Orekhov AN. In vitro models of anti-atherosclerotic effects of cardiovas- cultures. Inflammatory mechanisms, influenced by some cular drugs. Am J Cardiol 1990;66:23I-28I. 86 PRHSJ Vol. 29 No. 1 • March, 2010 15 Jargin.indd 86 2/5/2010 8:54:21 AM Concept of Serum Atherogenicity Questioned Jargin SV 8. Orekhov AN, Andrianova IV, Rekhter MD, Tertov VV, Andreeva ER, The determination of the concentration of a drug inhibiting Ragimov SE, Mironov AA. Beta-blockers: propranolol, metoprolol, a given physiological pathway by 50% (IC50) in a cellular system atenolol, pindolol, alprenolol and timolol, manifest atherogenicity on in vitro, ex vivo and in vivo models. Elimination of propranolol atherogenic bears very little connection to the response of complex units effects by papaverine. Atherosclerosis 1992;95:77-85. (i.e. body) where besides the direct cellular response to the 9. Orekhov AN, Tertov VV, Pivovarova EM. The effects of antihypertensive drug there is an interplay between tissues or organs affecting agents on atherosclerosis-related parameters of human aorta intimal cells. the agent. A critical component in this issue would be the Cardiology 1998;89:111-118. 10. Orekhov AN, Tertov VV, Kudryashov SA, Khashimov KhA, Smirnov excretion and/or metabolic routes of the drug that affects its VN. Primary culture of human aortic intima cells as a model for testing pharmacokinetics in vivo. For this reason, caution must be exerted antiatherosclerotic drugs. Effects of cyclic AMP, prostaglandins, calcium when determinations of IC50 obtained in cellular systems are used antagonists, antioxidants, and lipid-lowering agents. Atherosclerosis to predict the response of the body system to a given drug. 1986;60:101-110. 11. Tertov VV, Orekhov AN, Kudryashov SA, Klibanov AL, Ivanov NN, Torchi- Also, the response of cellular systems to an agent affecting lin VP, Smirnov VN. Cyclic nucleotides and atherosclerosis: studies in pri- the transport across the plasma membrane of a given substance mary culture of human aortic cells. Exp Mol Pathol 1987;47:377-389. could have opposite effects in the cell and the organism. For 12. Orekhov AN, Pivovarova EM, Sobenin IA, Yakushkin VV, Tertov VV. example, low transport of cholesterol into cells would be expected Use of cell culture for optimisation of direct antiatherogenic therapy with verapamil. Drugs 1992;44:105-110. to generate hypercholesterolemia and atherosclerosis (1-3). 13. Mosca L. Hyperlipidemia. In: Cardiology, 7th edition. (Crawford MN, Similarly, treatments with steroids that reduce glucose uptake into DiMarco JP, Paulus WJ, et al.), Edinburgh; Mosby, 2004: p. 73-90. cells are well known to be diabetogenic (4). For these reasons, the 14. Kraemer BF. Miller JW. Dyslipidemias In Clinical Pharmacology, 4th Edi- development of pharmacological treatments must be in the end, tion. (Carruthers SG, Hoffman BB, Melmon KL, Nierenberg DW), New York; McGrow-Hill, 2000: p. 552-580. based on in vivo animal studies followed by carefully designed 15. Cotran RS, Kumar V, Collins T. Robbins’ Pathologic Basis of Disease, clinical trials. Philadelphia; W.B. Saunders Co., 1999: p. 150-153, 418-509. 16. Marais AD. Familial hypercholesterolaemia. Clin Biochem Rev 2004; 25:49-68. Nelson escobales, Ph d 17. Jargin SV. Cell culture as a testing system for anti-atherogenic sub- Department of Physiology stances: a brief communication. Accessed on 04.11.2009. Available at: University of Puerto Rico School of Medicine URL: http://www.actapharmasciencia.org/archive.asp. Acta Pharm Sci 2008;50:237-240. references reply 1. Cotran RS, Kumar V, Collins T. Robbins’ Pathologic Basis of Disease, Philadelphia; W.B. Saunders Co., 1999: p. 150-153, 418-509. In this letter, Dr. Jargin raises the important issue on whether 2. Marais AD. Familial hypercholesterolaemia. Clin Biochem Rev 2004; 25:49-68. studies from simple cellular models can be used to model the 3. Jargin SV. Cell culture as a testing system for anti-atherogenic sub- response of organs, systems, or the body to anti-atherogenic stances: a brief communication. Accessed on 04.11.2009. Available at: treatments. The use of cellular systems in pharmacological URL: http://www.actapharmasciencia.org/archive.asp. Acta Pharm Sci studies is critical in the initial evaluation of drugs. However, 2008;50:237-240. 4. van Raalte DH, Ouwens DM, Diamant M. Novel insights into glucocor- their use to predict the response of the body to a given agent is ticoid-mediated diabetogenic effects: towards expansion of therapeutic limited as the author correctly indicates. options? Eur J Clin Invest 2009;39:81-93. PRHSJ Vol. 29 No. 1 • March, 2010 87 15 Jargin.indd 87 2/5/2010 8:54:22 AM.
Load more

Recommended publications
  • WO 2012/044761 Al
    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date _ . 5 April 2012 (05.04.2012) WO 2012/044761 Al (51) International Patent Classification: (81) Designated States (unless otherwise indicated, for every A61K 47/48 (2006.01) kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, (21) International Application Number: CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, PCT/US201 1/053876 DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, (22) International Filing Date: HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, 29 September 201 1 (29.09.201 1) KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, (25) Filing Language: English NO, NZ, OM, PE, PG, PH, PL, PT, QA, RO, RS, RU, (26) Publication Langi English RW, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, (30) Priority Data: ZM, ZW. 12/893,344 29 September 2010 (29.09.2010) US (84) Designated States (unless otherwise indicated, for every (71) Applicant (for all designated States except US): UNI¬ kind of regional protection available): ARIPO (BW, GH, VERSITY OF NORTH CAROLINA AT WILMING¬ GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, TON [US/US]; 601 South College Road, Wilmington, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, NC 28403 (US).
    [Show full text]
  • And Angiotensin II- Induced Changes by Calcium Antagonists in the Peripheral Circulation Ofanaesthetized Rabbits Robert P
    Br. J. Pharmac. (1985), 85, 75-87 Modification ofvasopressin- and angiotensin II- induced changes by calcium antagonists in the peripheral circulation ofanaesthetized rabbits Robert P. Hof Cardiovascular Unit of Preclinical Research, Sandoz Ltd, CH-4002 Basel, Switzerland 1 Investigations into the site of vasodilator and antivasoconstrictor activity of calcium antagonists previously performed in cats were extended to a second species, barbiturate-anaesthetized rabbits, and a second vasoconstrictor agent, vasopressin. 2 The dihydropyridine derivative darodipine (code name PY 108-068; 10, 30 and 100 pg kg-' i.v.) showed systemic haemodynamic effects comparable to those seen in cats at half these doses. Darodipine effected regional vasodilatation (measured with tracer microspheres) in the heart, brain and skeletal muscles as in cats. Only the vessels of the adrenals (dilated in rabbits but not in cats), and the kidneys and skin (constricted in rabbits but not in cats) responded differently to darodipine. 3 Angiotensin II (A II; 0.15 and 1.5 yg kg- min ')constricted the same vascular beds in rabbits as in cats, namely the heart, kidneys, small intestine, pancreas, spleen, skin and arterio-venous shunts (inferred from microspheres reaching the lungs), the only exceptions being the vessels of the stomach and liver (constriction only in cats) and the adrenals (constriction only in rabbits). 4 Darodipine (30 and 100 yg kg-') attenuated the A II-induced vasoconstriction in the same vascular beds in rabbits as in cats including the kidneys, which were constricted after administration of the antagonist alone. 5 These results indicate surprisingly small species differences for the vasodilator effects of darodipine as well as the attenuation of the vasoconstrictor effects of A II.
    [Show full text]
  • PHARMACEUTICAL APPENDIX to the TARIFF SCHEDULE 2 Table 1
    Harmonized Tariff Schedule of the United States (2020) Revision 19 Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE Harmonized Tariff Schedule of the United States (2020) Revision 19 Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 2 Table 1. This table enumerates products described by International Non-proprietary Names INN which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service CAS registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known.
    [Show full text]
  • Drugs for Primary Prevention of Atherosclerotic Cardiovascular Disease: an Overview of Systematic Reviews
    Supplementary Online Content Karmali KN, Lloyd-Jones DM, Berendsen MA, et al. Drugs for primary prevention of atherosclerotic cardiovascular disease: an overview of systematic reviews. JAMA Cardiol. Published online April 27, 2016. doi:10.1001/jamacardio.2016.0218. eAppendix 1. Search Documentation Details eAppendix 2. Background, Methods, and Results of Systematic Review of Combination Drug Therapy to Evaluate for Potential Interaction of Effects eAppendix 3. PRISMA Flow Charts for Each Drug Class and Detailed Systematic Review Characteristics and Summary of Included Systematic Reviews and Meta-analyses eAppendix 4. List of Excluded Studies and Reasons for Exclusion This supplementary material has been provided by the authors to give readers additional information about their work. © 2016 American Medical Association. All rights reserved. 1 Downloaded From: https://jamanetwork.com/ on 09/28/2021 eAppendix 1. Search Documentation Details. Database Organizing body Purpose Pros Cons Cochrane Cochrane Library in Database of all available -Curated by the Cochrane -Content is limited to Database of the United Kingdom systematic reviews and Collaboration reviews completed Systematic (UK) protocols published by by the Cochrane Reviews the Cochrane -Only systematic reviews Collaboration Collaboration and systematic review protocols Database of National Health Collection of structured -Curated by Centre for -Only provides Abstracts of Services (NHS) abstracts and Reviews and Dissemination structured abstracts Reviews of Centre for Reviews bibliographic
    [Show full text]
  • Drug Delivery System for Use in the Treatment Or Diagnosis of Neurological Disorders
    (19) TZZ __T (11) EP 2 774 991 A1 (12) EUROPEAN PATENT APPLICATION (43) Date of publication: (51) Int Cl.: 10.09.2014 Bulletin 2014/37 C12N 15/86 (2006.01) A61K 48/00 (2006.01) (21) Application number: 13001491.3 (22) Date of filing: 22.03.2013 (84) Designated Contracting States: • Manninga, Heiko AL AT BE BG CH CY CZ DE DK EE ES FI FR GB 37073 Göttingen (DE) GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO •Götzke,Armin PL PT RO RS SE SI SK SM TR 97070 Würzburg (DE) Designated Extension States: • Glassmann, Alexander BA ME 50999 Köln (DE) (30) Priority: 06.03.2013 PCT/EP2013/000656 (74) Representative: von Renesse, Dorothea et al König-Szynka-Tilmann-von Renesse (71) Applicant: Life Science Inkubator Betriebs GmbH Patentanwälte Partnerschaft mbB & Co. KG Postfach 11 09 46 53175 Bonn (DE) 40509 Düsseldorf (DE) (72) Inventors: • Demina, Victoria 53175 Bonn (DE) (54) Drug delivery system for use in the treatment or diagnosis of neurological disorders (57) The invention relates to VLP derived from poly- ment or diagnosis of a neurological disease, in particular oma virus loaded with a drug (cargo) as a drug delivery multiple sclerosis, Parkinsons’s disease or Alzheimer’s system for transporting said drug into the CNS for treat- disease. EP 2 774 991 A1 Printed by Jouve, 75001 PARIS (FR) EP 2 774 991 A1 Description FIELD OF THE INVENTION 5 [0001] The invention relates to the use of virus like particles (VLP) of the type of human polyoma virus for use as drug delivery system for the treatment or diagnosis of neurological disorders.
    [Show full text]
  • (12) United States Patent (10) Patent No.: US 8,486,374 B2 Tamarkin Et Al
    USOO8486374B2 (12) United States Patent (10) Patent No.: US 8,486,374 B2 Tamarkin et al. (45) Date of Patent: Jul. 16, 2013 (54) HYDROPHILIC, NON-AQUEOUS (56) References Cited PHARMACEUTICAL CARRIERS AND COMPOSITIONS AND USES U.S. PATENT DOCUMENTS 1,159,250 A 11/1915 Moulton 1,666,684 A 4, 1928 Carstens (75) Inventors: Dov Tamarkin, Maccabim (IL); Meir 1924,972 A 8, 1933 Beckert Eini, Ness Ziona (IL); Doron Friedman, 2,085,733. A T. 1937 Bird Karmei Yosef (IL); Alex Besonov, 2,390,921 A 12, 1945 Clark Rehovot (IL); David Schuz. Moshav 2,524,590 A 10, 1950 Boe Gimzu (IL); Tal Berman, Rishon 2,586.287 A 2/1952 Apperson 2,617,754 A 1 1/1952 Neely LeZiyyon (IL); Jorge Danziger, Rishom 2,767,712 A 10, 1956 Waterman LeZion (IL); Rita Keynan, Rehovot (IL); 2.968,628 A 1/1961 Reed Ella Zlatkis, Rehovot (IL) 3,004,894 A 10/1961 Johnson et al. 3,062,715 A 11/1962 Reese et al. 3,067,784. A 12/1962 Gorman (73) Assignee: Foamix Ltd., Rehovot (IL) 3,092.255. A 6, 1963 Hohman 3,092,555 A 6, 1963 Horn 3,141,821 A 7, 1964 Compeau (*) Notice: Subject to any disclaimer, the term of this 3,142,420 A 7/1964 Gawthrop patent is extended or adjusted under 35 3,144,386 A 8/1964 Brightenback U.S.C. 154(b) by 1180 days. 3,149,543 A 9, 1964 Naab 3,154,075 A 10, 1964 Weckesser 3,178,352 A 4, 1965 Erickson (21) Appl.
    [Show full text]
  • Federal Register / Vol. 60, No. 80 / Wednesday, April 26, 1995 / Notices DIX to the HTSUS—Continued
    20558 Federal Register / Vol. 60, No. 80 / Wednesday, April 26, 1995 / Notices DEPARMENT OF THE TREASURY Services, U.S. Customs Service, 1301 TABLE 1.ÐPHARMACEUTICAL APPEN- Constitution Avenue NW, Washington, DIX TO THE HTSUSÐContinued Customs Service D.C. 20229 at (202) 927±1060. CAS No. Pharmaceutical [T.D. 95±33] Dated: April 14, 1995. 52±78±8 ..................... NORETHANDROLONE. A. W. Tennant, 52±86±8 ..................... HALOPERIDOL. Pharmaceutical Tables 1 and 3 of the Director, Office of Laboratories and Scientific 52±88±0 ..................... ATROPINE METHONITRATE. HTSUS 52±90±4 ..................... CYSTEINE. Services. 53±03±2 ..................... PREDNISONE. 53±06±5 ..................... CORTISONE. AGENCY: Customs Service, Department TABLE 1.ÐPHARMACEUTICAL 53±10±1 ..................... HYDROXYDIONE SODIUM SUCCI- of the Treasury. NATE. APPENDIX TO THE HTSUS 53±16±7 ..................... ESTRONE. ACTION: Listing of the products found in 53±18±9 ..................... BIETASERPINE. Table 1 and Table 3 of the CAS No. Pharmaceutical 53±19±0 ..................... MITOTANE. 53±31±6 ..................... MEDIBAZINE. Pharmaceutical Appendix to the N/A ............................. ACTAGARDIN. 53±33±8 ..................... PARAMETHASONE. Harmonized Tariff Schedule of the N/A ............................. ARDACIN. 53±34±9 ..................... FLUPREDNISOLONE. N/A ............................. BICIROMAB. 53±39±4 ..................... OXANDROLONE. United States of America in Chemical N/A ............................. CELUCLORAL. 53±43±0
    [Show full text]
  • Stembook 2018.Pdf
    The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances FORMER DOCUMENT NUMBER: WHO/PHARM S/NOM 15 WHO/EMP/RHT/TSN/2018.1 © World Health Organization 2018 Some rights reserved. This work is available under the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 IGO licence (CC BY-NC-SA 3.0 IGO; https://creativecommons.org/licenses/by-nc-sa/3.0/igo). Under the terms of this licence, you may copy, redistribute and adapt the work for non-commercial purposes, provided the work is appropriately cited, as indicated below. In any use of this work, there should be no suggestion that WHO endorses any specific organization, products or services. The use of the WHO logo is not permitted. If you adapt the work, then you must license your work under the same or equivalent Creative Commons licence. If you create a translation of this work, you should add the following disclaimer along with the suggested citation: “This translation was not created by the World Health Organization (WHO). WHO is not responsible for the content or accuracy of this translation. The original English edition shall be the binding and authentic edition”. Any mediation relating to disputes arising under the licence shall be conducted in accordance with the mediation rules of the World Intellectual Property Organization. Suggested citation. The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances. Geneva: World Health Organization; 2018 (WHO/EMP/RHT/TSN/2018.1). Licence: CC BY-NC-SA 3.0 IGO. Cataloguing-in-Publication (CIP) data.
    [Show full text]
  • Anti-Atherosclerotic Drugs from Natural Products
    s Chemis ct try u d & Orekhov, Nat Prod Chem Res 2013, 1:4 o r R P e s l e a r a DOI: 10.4172/2329-6836.1000121 r u t c h a N Natural Products Chemistry & Research ISSN: 2329-6836 Review Article Open Access Anti-atherosclerotic Drugs from Natural Products Alexander N Orekhov1,2* 1Institute for Atherosclerosis Research, Skolkovo Innovative Center, Moscow, Russia 2Institute of General Pathology and Pathophysiology, Russian Academy of Medical Sciences, Russia Abstract Atherosclerosis is the cause of more than 50% mortality in industrial countries. Atherosclerosis develops over many years, so the anti-atherosclerotic therapy should be long-term or even lifelong. Tachyphylaxis, long-term toxicity and cost amongst other issues may present problems for the use of conventional medications in the long-term. Drugs based on natural products can be a good alternative. We have developed a series of natural compounds that are specifically designed to act at the vessel wall and modulate the atherosclerotic lesion. Clinical efficacy was determined in atherosclerosis regression studies with ultrasound examination of carotid arteries. The AMAR study (Atherosclerosis Monitoring and Atherogenicity Reduction) was designed to estimate the effect of two-year treatment with time-released garlic-based drug Allicor on the progression of carotid atherosclerosis in asymptomatic men in double-blinded placebo-controlled randomized clinical trial. The primary outcome was the rate of atherosclerosis progression, measured by high-resolution B-mode ultrasonography as the increase in carotid intima-media thickness (IMT) of the far wall of common carotid arteries. The mean rate of IMT changes in Allicor-treated group was significantly different from the placebo group in which there was moderate progression.
    [Show full text]
  • Subject Index
    Subject Index 84 905 induction ofcontractions in guinea-pig intestinal A effect of galIamine, gallopamil and nifedipine on smooth muscle, effect of pardaxin, 82, 43 response to, in taenia of the guinea-pig caecum. induction ofcontractions, effect ofnisoldipine in A23187, induction of relaxations in vascular smooth 83, 145 skinned or intact muscles in rabbit coronary muscle, effect of endothelial damage, 87, 713 effect of guanethidine on content of rat sym- arteries, 33, 243 -,release of prostacyclin and prostaglandin E2 pathetic ganglia, 82, 827 induction ofcontractions in cat tracheal smooth from pig aortic endothelial cells, bioassay, 87, effect of 5-HT spontaneous and electrically- muscle, effect of isoprenaline, 83, 677 685 evoked release from guinea-pig myenteric plexus, induction ofcontractions in cat tracheal smooth -,see Calcium Ionopbore A23187 88, 85, 529 muscle, role of stored calcium, 3, 667 A23187, effect on human neutrophil chemokinesis effect of ketamine and pentobarbitone on rat -,induction of contractions of guinea-pig lung and granular enzyme secretion, 91, 557 cerebral cortex concentrations, 82, 339 parenchyma strips, 34, 801 Abdominal comtriction test, sensitivity to gs- and effect of MDL 12, 330A in frog pectoris nerve- induction ofcontractions ofsmooth muscle in rat s-opioid receptor agonists in the mouse, 91, 823 muscle preparations on release, 88, 799 fundus, 34, 897 Abnormal automacity, barium- or strophanthidin- effect of methylxanthines on release from induction of contractions in rat fundus, lack of induced,
    [Show full text]
  • Permanently Charged Sodium and Calcium Channel Blockers As Anti-Inflammatory Agents
    (19) TZZ ¥Z¥_T (11) EP 2 995 303 A1 (12) EUROPEAN PATENT APPLICATION (43) Date of publication: (51) Int Cl.: 16.03.2016 Bulletin 2016/11 A61K 31/165 (2006.01) A61K 31/277 (2006.01) A61K 45/06 (2006.01) A61P 25/00 (2006.01) (2006.01) (2006.01) (21) Application number: 15002768.8 A61P 11/00 A61P 13/00 A61P 17/00 (2006.01) A61P 1/00 (2006.01) (2006.01) (2006.01) (22) Date of filing: 09.07.2010 A61P 27/02 A61P 29/00 A61P 37/08 (2006.01) (84) Designated Contracting States: (72) Inventors: AL AT BE BG CH CY CZ DE DK EE ES FI FR GB • WOOLF, Clifford, J. GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO Newton, MA 02458 (US) PL PT RO SE SI SK SM TR • BEAN, Bruce, P. Waban, MA 02468 (US) (30) Priority: 10.07.2009 US 224512 P (74) Representative: Lahrtz, Fritz (62) Document number(s) of the earlier application(s) in Isenbruck Bösl Hörschler LLP accordance with Art. 76 EPC: Patentanwälte 10797919.7 / 2 451 944 Prinzregentenstrasse 68 81675 München (DE) (71) Applicants: • President and Fellows of Harvard College Remarks: Cambridge, MA 02138 (US) This application was filed on 25-09-2015 as a • THE GENERAL HOSPITAL CORPORATION divisional application to the application mentioned Boston, MA 02114 (US) under INID code 62. • CHILDREN’S MEDICAL CENTER CORPORATION Boston, Massachusetts 02115 (US) (54) PERMANENTLY CHARGED SODIUM AND CALCIUM CHANNEL BLOCKERS AS ANTI-INFLAMMATORY AGENTS (57) The present invention relates to a composition or a kit comprising N-methyl etidocaine for use in a method for treating neurogenic inflammation in a patient, wherein the kit further comprises instructions for use.
    [Show full text]
  • Calcium Channel Ca2+ Channels;Ca Channels
    Calcium Channel Ca2+ channels;Ca channels Calcium channel is an ion channel which displays selective permeability to calcium ions. It is sometimes synonymous as voltage-dependent calcium channel, although there are also ligand-gated calcium channels. Voltage-gated calcium (CaV) channels catalyse rapid, highly selective influx of Ca 2+ into cells despite a 70-fold higher extracellular concentration of Na +. Some calcium channel blockers have the added benefit of slowing your heart rate, which can further reduce blood pressure, relieve chest pain (angina) and control an irregular heartbeat. www.MedChemExpress.com 1 Calcium Channel Inhibitors & Modulators (+)-Kavain ABT-639 Cat. No.: HY-B1671 Cat. No.: HY-19721 Bioactivity: (+)-Kavain, a main kavalactone extracted from Piper Bioactivity: ABT-639 is a novel, peripherally acting, selective T-type methysticum, has anticonvulsive properties, attenuating Ca2+ channel blocker. vascular smooth muscle contraction through interactions with voltage-dependent Na + and Ca 2+ channels [1]. (+)-Kav… Purity: 99.98% Purity: 99.15% Clinical Data: No Development Reported Clinical Data: Phase 2 Size: 10mM x 1mL in DMSO, Size: 10mM x 1mL in DMSO, 5 mg, 10 mg 1 mg, 5 mg, 10 mg, 50 mg, 100 mg ABT-639 hydrochloride Acetylcholine chloride Cat. No.: HY-101616 (Ach; ACh chloride) Cat. No.: HY-B0282 Bioactivity: ABT-639 hydrochloride is a novel, peripherally acting, Bioactivity: Acetylcholine (chloride) is a common neurotransmitter found selective T-type Ca2+ channel blocker. in the central and peripheral nerve system. Purity: >98% Purity: 98.0% Clinical Data: No Development Reported Clinical Data: Launched Size: 1 mg, 5 mg, 10 mg, 20 mg Size: 10mM x 1mL in DMSO, 1 g, 5 g ACT-709478 AE0047 Hydrochloride Cat.
    [Show full text]